From Benchtop to Breakthrough:
Legacy and Leadership at Bristol-Myers Squibb Oncology
A Bristol-Myers Squibb researcher working on synthesis and selection of monoclonal antibodies.
Bristol-Myers Squibb provided its first anticancer medication for patients more than four decades ago – a medicine that’s still being prescribed today. Now, we’ve developed an oncology R&D portfolio of nearly 20 compounds and, in the past five years, we’ve launched four new anticancer medications. All told, Bristol-Myers Squibb is conducting about 200 ongoing oncology clinical trials, addressing 20 different tumor types.
Clearly, Bristol-Myers Squibb is reasserting its leadership in cancer therapy and oncology research. And, at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, we are featuring nearly 100 scientific abstracts on our approved and investigational oncology compounds.
Through our internal Discovery programs and our external String of Pearls strategy of innovative alliances, partnerships and acquisitions, we have built a robust pipeline of early and late-stage anticancer compounds. Of those four recently-launched anticancer medicines, two are internal discoveries and two represent assets we developed from external acquisitions or partnerships.
Now, Bristol-Myers Squibb’s oncology pipeline represents a wide range of treatment platforms, including traditional small-molecule cytotoxins as well as biologics and other novel and targeted approaches. One innovative approach is immuno-oncology. In this area we have both small molecules and biologic programs that are designed to enhance the cancer-killing power of the immune system or increase the visibility of the tumor to the immune system. Another pioneering approach is antibody drug conjugates, in which a cancer-killing drug is linked to a monoclonal antibody. The antibody specifically targets a particular cancer cell antigen, thus ignoring most normal cells and delivering the drug directly to the cancer cell. Bristol-Myers Squibb has ongoing clinical programs for antibody drug conjugates, immuno-oncology drugs as well as other novel approaches to fight the disease across multiple tumor types.
The hallmark of Bristol-Myers Squibb’s legacy of innovative cancer research and breakthrough treatments – true 40 years ago as it is today – is our unwavering commitment to patients.
Visit msnbc.com for breaking news, world news, and news about the economy